Last reviewed · How we verify
Oxaliplatin + 5-Fluorouracil/Leucovorin
Oxaliplatin + 5-Fluorouracil/Leucovorin is a Platinum-based chemotherapy combination; antimetabolite Small molecule drug developed by First Affiliated Hospital of Zhejiang University. It is currently in Phase 3 development for Metastatic colorectal cancer, Adjuvant treatment of stage III colorectal cancer, Advanced gastric cancer.
This combination uses oxaliplatin (a platinum-based DNA crosslinker) plus 5-fluorouracil and leucovorin (a thymidylate synthase inhibitor with a folate cofactor) to damage cancer cell DNA and disrupt nucleotide synthesis.
This combination uses oxaliplatin (a platinum-based DNA crosslinker) plus 5-fluorouracil and leucovorin (a thymidylate synthase inhibitor with a folate cofactor) to damage cancer cell DNA and disrupt nucleotide synthesis. Used for Metastatic colorectal cancer, Adjuvant treatment of stage III colorectal cancer, Advanced gastric cancer.
At a glance
| Generic name | Oxaliplatin + 5-Fluorouracil/Leucovorin |
|---|---|
| Sponsor | First Affiliated Hospital of Zhejiang University |
| Drug class | Platinum-based chemotherapy combination; antimetabolite |
| Target | DNA (oxaliplatin); thymidylate synthase (5-fluorouracil) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Oxaliplatin forms platinum-DNA adducts that prevent DNA replication and transcription, inducing apoptosis in rapidly dividing cells. 5-Fluorouracil (5-FU) is converted to active metabolites that inhibit thymidylate synthase, blocking dTMP synthesis and disrupting DNA synthesis; leucovorin (folinic acid) enhances 5-FU efficacy by stabilizing the 5-FU–thymidylate synthase complex. Together, these agents provide synergistic cytotoxic effects against colorectal and other solid tumors.
Approved indications
- Metastatic colorectal cancer
- Adjuvant treatment of stage III colorectal cancer
- Advanced gastric cancer
- Pancreatic cancer
Common side effects
- Peripheral neuropathy
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Diarrhea
- Mucositis
- Fatigue
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (PHASE3)
- Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) (PHASE2)
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (PHASE1)
- Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (PHASE3)
- A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxaliplatin + 5-Fluorouracil/Leucovorin CI brief — competitive landscape report
- Oxaliplatin + 5-Fluorouracil/Leucovorin updates RSS · CI watch RSS
- First Affiliated Hospital of Zhejiang University portfolio CI
Frequently asked questions about Oxaliplatin + 5-Fluorouracil/Leucovorin
What is Oxaliplatin + 5-Fluorouracil/Leucovorin?
How does Oxaliplatin + 5-Fluorouracil/Leucovorin work?
What is Oxaliplatin + 5-Fluorouracil/Leucovorin used for?
Who makes Oxaliplatin + 5-Fluorouracil/Leucovorin?
What drug class is Oxaliplatin + 5-Fluorouracil/Leucovorin in?
What development phase is Oxaliplatin + 5-Fluorouracil/Leucovorin in?
What are the side effects of Oxaliplatin + 5-Fluorouracil/Leucovorin?
What does Oxaliplatin + 5-Fluorouracil/Leucovorin target?
Related
- Drug class: All Platinum-based chemotherapy combination; antimetabolite drugs
- Target: All drugs targeting DNA (oxaliplatin); thymidylate synthase (5-fluorouracil)
- Manufacturer: First Affiliated Hospital of Zhejiang University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic colorectal cancer
- Indication: Drugs for Adjuvant treatment of stage III colorectal cancer
- Indication: Drugs for Advanced gastric cancer
- Compare: Oxaliplatin + 5-Fluorouracil/Leucovorin vs similar drugs
- Pricing: Oxaliplatin + 5-Fluorouracil/Leucovorin cost, discount & access